| Balance Sheets | 2025-06-30 | |||
|---|---|---|---|---|
| Prepaid expenses and other current assets | 48,904 | |||
| Cash | 822 | |||
| Total current assets | 49,726 | |||
| Deferred offering costs | 0 | |||
| Cash and investments held in trust account | 235,155,966 | |||
| Total assets | 235,205,692 | |||
| Promissory note related party-Related Party | 0 | |||
| Accounts payable and accrued expenses | 147,453 | |||
| Accrued offering costs | 153,988 | |||
| Total current liabilities | 301,441 | |||
| Deferred underwriting fee payable | 6,900,000 | |||
| Total liabilities | 7,201,441 | |||
| Share subscription receivable | 695,825 | |||
| Accumulated deficit | -6,456,942 | |||
| Ordinary shares, 0.0001 par value 220,000,000 shares authorized 10,517,143 and 9,857,143 shares issued and outstanding, excluding 20,000,000 and 0 shares subject to redemption as of june 30, 2025 and december 31, 2024, respectively | 1,052 | |||
| Additional paid-in capital | 0 | |||
| Total shareholders deficit | -7,151,715 | |||
| Ordinary shares subject to possible redemption, 23,000,000 shares at redemption value of 10.22 and 0 per share as of june 30, 2025 and december 31, 2024, respectively | 235,155,966 | |||
| Total liabilities and shareholders deficit | 235,205,692 | |||
Drugs Made In America Acquisition Corp. (DMAAU)
Drugs Made In America Acquisition Corp. (DMAAU)